Siegfried Holding (SFZN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 3.2B
Fair value as of: Jul 17, 2026
From 23 valuation models · updated 23 days ago
Fair value updated Jul 17, 2026, revised from CHF 53.11 to CHF 52.72 (−0.7%) since Jun 24, 2026. Share price +12.1% over the past month.
A solid business, but screening 34% overvalued on our models.
What matters now
- The model range is unusually wide (CHF 26.18 to CHF 91.25). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range CHF 55.98 – CHF 117.09 · fair‑value band CHF 26.18 – CHF 91.25 · the CHF 79.65 price screens above the CHF 52.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Siegfried Holding (SFZN) currently trades at CHF 79.65, while our model-based Fair Value estimate is CHF 52.72, implying the stock looks roughly 33.8% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Siegfried Holding generated revenue of CHF 1.3B at a net margin of 12.7%. Revenue grew 5.0% year over year. It earns a return on equity of 16.0%. Net debt stands at CHF 472M. Fundamentals as of Jul 17, 2026
Our scenario range runs from CHF 26.18 (bear case) to CHF 91.25 (bull case); at CHF 79.65, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -34%, SFZN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (CHF 76.56) versus Dividend Discount (CHF 5.60). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs.
Full company description
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Siegfried Holding reported revenue of CHF 1.3B in FY2025 versus CHF 1.1B in FY2021, a compound +4.8%/yr. Reported net income was CHF 169M in FY2025, compounding +15.2%/yr from FY2021.
SFZN screens 34% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Siegfried Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Siegfried Holding (SFZN) overvalued or undervalued?
What is the fair value of SFZN?
What is the quality score of SFZN?
What is the revenue of Siegfried Holding (SFZN)?
What is the net profit margin of SFZN?
Does Siegfried Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Siegfried Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.